Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron gets notice of US cryptopreservation patent

ReNeuron is using cryopreservation technology in its CTX stem cell line
ReNeuron gets notice of US cryptopreservation patent
Ongoing UK clinical trials in both stroke disability and critical limb ischaemia include the technology

ReNeuron (LON:RENE) has received a  Notice of Allowance from the US Patent and Trademark Office for a key patent application covering its cell cryopreservation technology. 

The patent application contains broad claims relating to cryopreserved neural, retinal and mesenchymal stem cells using a formulation developed by ReNeuron that is free of toxic cryopreservants.  

ReNeuron is using cryopreservation technology in its CTX stem cell line to derive a cryopreserved, long shelf life cell therapy candidate, designated CTXcryo.

Ongoing UK clinical trials in both stroke disability and critical limb ischaemia include the technology.  

Olav Hellebø, ReNeuron’s chief executive added the company had invested heavily in patents in recent and the US Notice of Allowance for cell cryopreservation was another important addition.

PhilW.jpg
Why Invest In ReNeuron Group Plc? Read More Here

Register here to be notified of future RENE Company articles
View full RENE profile

ReNeuron Group Plc Timeline

Video
October 28 2016
Article
October 28 2016

Related Articles

Concept of a DNA strand
September 13 2016
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making incredible advances altering the inner workings of the human body to tackle deadly diseases.
drug resistant infections such as E. coli and Pseudomonas
October 02 2016
In vivo testing confirmed that Redx’s novel compounds were highly effective against certain drug resistant strains of bacteria.
Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.